| Literature DB >> 19764992 |
Emeline de Viron1, Laurent Knoops, Thierry Connerotte, Caroline Smal, Lucienne Michaux, Pascale Saussoy, Pascal Vannuffel, Eline Beert, Marie-Christiane Vekemans, Cédric Hermans, Françoise Bontemps, Eric Van Den Neste.
Abstract
The functional evaluation of ataxia telangiectasia mutated (ATM) and p53 was recently developed in B-cell chronic lymphocytic leukaemia (B-CLL), a disease in which the response to DNA damage is frequently altered. We identified a novel biomarker of chemosensitivity based on the induction of DNA damage by the purine nucleoside analogues (PNA) fludarabine and 2-chlorodeoxyadenosine (CdA). Using genome-wide expression profiling, it was observed that, in chemosensitive samples, PNA predominantly increased the expression of p53-dependent genes, among which PLK2 was the most highly activated at early time points. Conversely, in chemoresistant samples, p53-dependent and PLK2 responses were abolished. Using a quantitative real time polymerase chain reaction, we confirmed that PNA dose- and time-dependently increased PLK2 expression in chemosensitive but not chemoresistant B-CLL samples. Analysis of a larger cohort of B-CLL patients showed that cytotoxicity induced by PNA correlated well with PLK2 mRNA induction. Interestingly, we observed that failure to up-regulate PLK2 following PNA and chemoresistance were not strictly correlated with structural alterations in the TP53 gene. In conclusion, we propose that testing PLK2 activation after a 24-h incubation with PNA could be used to investigate the functional integrity of DNA damage-response pathways in B-CLL cells, and predict clinical sensitivity to these drugs.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19764992 DOI: 10.1111/j.1365-2141.2009.07900.x
Source DB: PubMed Journal: Br J Haematol ISSN: 0007-1048 Impact factor: 6.998